Understanding Human Glycosylation Disorders: Biochemistry Leads the Charge

Hudson H. Freeze

Genetic Disease Program, Sanford-Burnham Medical Research Institute, La Jolla CA, 92037

To whom correspondence should be addressed: Hudson H. Freeze, Genetic Disease Program, Sanford Children’s Health Research Center, Sanford-Burnham Medical Research Institute, 10901 N. Torrey Pines Rd., La Jolla, CA, USA, Tel: (858) 646-3142; Fax: (858) 795-5381; E-mail: hudson@sanfordburnham.org.

SUMMARY

Nearly 70 inherited human glycosylation disorders span a breathtaking clinical spectrum impacting nearly every organ system and launching a family-driven diagnostic odyssey. Advances in genetics, especially next generation sequencing, propelled discovery of many glycosylation disorders in single and multiple pathways. Interpretation of whole exome sequencing results, insights into pathological mechanisms and possible therapies will hinge on biochemical analysis of patient-derived materials and animal models. Biochemical diagnostic markers and readouts offer a physiological context to confirm candidate genes. Recent discoveries suggest novel perspectives for textbook biochemistry and novel research opportunities. Basic science and patients are the immediate beneficiaries of this bi-directional collaboration.

ORIENTATION

Recent progress in exome sequencing (1, 2) place biochemistry in the enviable position of having to explain how patients with inherited glycosylation disorders develop their symptoms and how to suggest therapies to treat them. The technology to identify defective genes is no longer rate-limiting; it is available, inexpensive, and in demand. Informatics effectively sifts through predictions of damaging mutations in hundreds of cases of patients with unknown genetic disorders (3, 4). Now, biochemistry must step in to provide context and functional information for genes, some known only by letters and numbers.

Each of these developments increases biochemical momentum. The recent report from the National Academy of Sciences National Research Council on the Future of Glycosciences (5) alerts the scientific community, funding agencies, and politicians to this often overlooked field. The creation of the National Center for Advancing Translational Sciences (NCATS) marks a fuller commitment of the NIH to translational medicine. The goal of the newly formed Centers for Mendelian Genomics is to solve the genetic basis of over 3500 rare disorders (6). About 70 known genetic disorders affect glycan synthesis and it is estimated that 2% of the genome encodes currently known glycosylation reactions (7). The bottom line: many glycosylation disorders are known, many more will be found, and gene sequencing technology will deliver diverse medical specialities to Glycobiology in search of biochemical validation and deeper understanding for therapeutic options. This review will focus on how clinical medicine and basic science, now more than ever, generate an immediate, symbiotic, cross-fertilizing partnership. Several recently discovered glycosylation disorders will also raise important questions for further biochemical investigation.

The collection of glycosylation disorders cause abnormalities in nearly every organ system (7, 8). This means that physicians from every specialty will likely encounter patients who carry glycosylation defects. While near-term exome (or genome) sequencing will undoubtedly indicate either known or predictable glycosylation genes within their clinical arena, other genes may appear on the “fringes” of the current understanding of what constitutes a “glycosylation gene.” Examples follow. Essentially all of the known glycosylation biosynthetic pathways are included in these disorders. Rather than cover all of them, the review will focus on recent discoveries that generate novel perspectives and orient future areas for research. A general point to remember is that...
Understanding Human Glycosylation Disorders: Biochemistry Leads the Charge

while many of the disorders are restricted to a specific biosynthetic pathway such as the assembly of the precursor glycan for N-glycosylation, others such as those that generate metabolic precursors or Golgi trafficking complexes can impact multiple pathways.

GLYCOSYLATION PATHWAYS

Mammals have 8 major glycosylation pathways in the ER-Golgi (7-9). Three of these will be highlighted here since they house most of the newly discovered glycosylation disorders. N-glycosylation (Figure 1) occurs in the ER during or soon after the synthesis of nascent proteins. UDP-GlcNAc, GDP-Man, Dol-P-Man and Dol-P-Glc provide the activated precursors to construct a glycan composed of Glc 3 Man 9 GlcNAc 2, which is built stepwise onto a dolichol acceptor embedded in the membrane. The glycan from this lipid-linked oligosaccharide (LLO) precursor is transferred en bloc to asparagine (N) within an NXT/S context of the protein acceptors. Remodeling (processing) of the protein-bound chain excises glucose in the ER, a variable number of mannose units, (ER and Golgi) and this can be followed by the addition of variable amounts of GlcNAc, Gal, Fuc and Sialic acid (Golgi). Decorate some chains with sulfate or phosphate and send the glycoproteins to destinations within the cell, on its surface, or beyond (10).

Glycosylphosphatidylinositol (GPI) anchors are assembled stepwise on phosphatidylinositol in the ER membrane (11) starting with transfer of GlcNAc by a protein complex on the cytoplasmic face (PIG-A), followed by de-N-acetylation (PIG-L). Flip to the luminal side for addition an extra acyl chain to inositol (PIG-W). This is followed by addition of 2 mannose units (PIG-M and PIG-V), ethanolamine phosphate (PIG-N), another mannose (PIG-B) and two ethanolamine phosphates (PIG-O, PIG-F). The entire sugar-lipid unit is transferred to proteins with the appropriate C-terminal amino acid sequence using a multimeric transamidase complex. A deacylase removes the acyl chain generated by PIG-W (Figure 2).

O-Mannose based glycosylation structures and biosynthetic pathways are incomplete and studies are ongoing. Selected Ser/Thr residues on target proteins (primarily α-dystroglycan) use Dol-P-Man and a POMT1/POMT2 complex to begin the assembly with mannose (12). Addition of GlcNAc (POMGnT1) and Gal (BGal4-T) and sialic acid make simple structures. More complex branched glycans add GlcNAc and sulfated glucuronic acid (13). Beyond this point, the biosynthetic pathways are unclear. Some functionally important chains are phosphorylated to generate Man-6-P and receive a glycosaminoglycan-like polymer containing alternating α13Xyl and β13GlcA residues (14). Man-6-P is converted to a diester of unknown composition (15). The prerequisite glycan structures, order of addition, and donor substrates are undefined. Human glycosylation disorders, the α-dystroglycanopathies, have been key to solving this pathway. Mutations in genes Fukutin and FKRP that define glycosylation-related muscular dystrophies encode putative glycosyltransferases in search of both donors and acceptors (13).

CLINICAL AND GENETIC NOMENCLATURE

Many human glycosylation disorders were first described by physicians and based on their patients’ clinical presentations, since the genetic basis was unknown. A good example is the severity-based categories of α-dystroglycanopathies that effect the addition of O-mannose-based glycans on α-dystroglycan complex in muscle cells (12). A revised nomenclature was proposed (16). However, many cases still lack specific diagnoses as the search for new gene defects continues.

One group of glycosylation disorders were called Carbohydrate Deficient Glycoprotein Syndromes (CDGS) and then Congenital Disorders of Glycosylation (CDG) subdivided into two groups based on whether the mutated genes affected the addition of N-glycans (Type I) or their processing (Type II). The latest simplified version (18) employs non-italicized gene name followed by –CDG, e.g., CDG-Ia is now PMM2-CDG. Both systems will likely co-exist for some time.

BIOCHEMICAL MARKERS FOR GLYCOSYLATION DISORDERS

Potential glycosylation disorders can be assessed with biochemical biomarkers (19-21). However, markers do not identify the genetic defect. Serum transferrin (Tf) is the best marker
for detecting most disorders affecting the N-glycosylation pathway (8, 22). Tf has two N-linked glycans each containing two sialic acids. Mass spectrometry, HPLC or isoelectric focusing easily identifies disorders in which one or both of the sites are unoccupied. The same methods yield different abnormal patterns when the defects alter N-glycan processing. Defects in GPI anchor synthesis can often be identified using antibodies (20, 23) against the GPI anchor itself or more commonly GPI-anchored proteins such as CD59 on leukocytes. The α-dystroglycanopathies caused by defects in O-mannose based glycans can be recognized in muscle biopsies using monoclonal antibodies (IIH6 and VIA4) directed against the glycan itself (24). Obviously, obtaining muscle is more invasive than a simple blood test and would not be routinely done as an inexpensive first step. There are no simple markers for defects in GAG chain synthesis.

REVOLUTION IN GENE DISCOVERY

Previously, the genes responsible for most glycosylation disorders were identified by biochemical analysis of fibroblasts and serum glycans (8, 25). Now genetic mapping techniques have largely replaced this approach (1, 7, 8). This is especially important for finding defects in consanguineous families. Plummeting sequencing costs, lightning speed, improved informatic analysis, and widespread availability of technology puts these approaches in hand for solving glycosylation and other rare disorders. However, employing biomarkers as a first step quickly focuses the search to glycosylation, and more importantly, it provides a metabolic context for candidate genes. In the past 2 years, three defects were solved with traditional biochemical analysis and 5 by autozygosity mapping, linkage analysis or targeted genomic arrays. Ten defects were solved with state-of-the-art whole-exome analysis (Table 1).

The mutated gene must be shown to impair the function of the protein or cause pathology. In many cases, the effects of the mutation on RNA splicing or protein structure are predicted based on multiple programs such as SIFT (26), PolyPhen (27) or Condel (28) along with evolutionary conservation (29) (PhyloP) and frequency of the occurrence of the non-synonymous SNP. A physiologically relevant approach is to complement the patient’s fibroblasts with the normal allele of the mutated gene and show it corrects abnormal insufficient glycosylation (30-33). Another is to complement yeast or mammalian cells with defects in the candidate gene with the normal human allele, but not the mutated version. Restoration of cell growth, lectin binding or normal glycosylation of target proteins is typically done. In more complex systems (flies, fish, worms and mice) functional knockdown of the gene that generates a similar gross phenotype is taken as evidence that the mutations in the gene are damaging (34-36).

REDISCOVERING SUGAR METABOLISM

The well-established metabolic pathways connecting monosaccharide metabolism to protein glycosylation are incomplete (Figure 3). They show potential reactions, but do not reflect contributions of different sources to convergent pathways, cell and organ preferences, or allowance for metabolic states. Glycosylation disorders and models of these diseases are adding unexpected dimensions to the two-dimensional pathways (10, 37-39).

Patients deficient in MPI (Fruc-6-P<-> Man-6-P) lack sufficient mannose-6-P for full N-glycosylation. Clearly, glucose is a vital source of this precursor. However, modest daily supplements of mannose correct most of the patients’ glycosylation deficiencies (40, 41). On the other hand, hypomorphic PMM2-deficient patients (Man-6-P→ Man-1-P) do not benefit from mannose treatment. In mice, null alleles of either gene are embryonic lethal (E2-10.5) (42, 43). Compound heterozygous mice carrying patient-equivalent mutations in Pmm2 with ~10% residual enzymatic activity also die in mid-gestation. Surprisingly, providing mannose to the dams’ in their drinking water (intake ~ 25mg/day) bypasses a critical block and produces viable, full term embryos that continue to thrive beyond weaning without mannose (38). This result suggests that the critical period is a gestational glycosylation insufficiency. It is premature to advise at-risk parents to consider mannose supplements in an attempt to ameliorate potential defects in their glycosylation-deficient pathways (7).

Zebrafish morphants deficient in pmm2 or mpi have significant morphological abnormalities in many ways comparable to the patients (35, 44).
The mpi morphants can be substantially rescued with 50mM mannose in the water, but supplementation was only required in the first 24 hr. Removal of mannose or continued treatment beyond that time did not alter the outcome. The pmm2 morphant fish were not given mannose, but reducing the metabolic flux through the glycosylation pathway by generating double morphants deficient in both pmm2 and mpi actually improved the pmm2 phenotype. A curious aspect is that pmm2 morphants have increased amount of Man-6-P. The accumulation correlates with the loss of LLO and appearance of free oligosaccharides, presumably released from the LLO (45, 46). These results recall important in vitro studies showing that increased Man-6-P levels lead to degradation of mature LLO precursor and release of the intact glycan. This suggests that Man-6-P may function as an intracellular sensor or signaling molecule. The mechanism is unknown.

Congenital myasthenic syndromes result from impaired signal transmission at the neuromuscular synapse (47). Using genetic linkage, one study (48) identified 13 unrelated families with mutations in glutamine-fructose-6-phosphate transaminase 1 (GFPT1) used for UDP-GlcNAc synthesis supplying most glycosylation pathways. No specific pathway was shown to cause pathology, but knockdown of the zebrafish ortholog gfpt1 altered muscle fiber morphology and impaired neuromuscular junction development in embryos. A surprising feature of this study was that some GFPT1 mutations had no effect on enzymatic activity, suggesting that the organization or localization of the enzyme in the cytoplasm is important for normal function.

Another whole exome study (49) describes 5 patients with a limb-girdle myasthenia syndrome and mutations in DPAGT1, the first enzyme in LLO synthesis and well-known cause of CDG (7, 8). The deficiency may be due to a failure to export acetylcholine receptors to the endplate. No enzymatic assay was performed, but patients had abnormal transferrin and a much milder phenotype than seen in previous CDG patients (50).

Whole exome and other genetic mapping studies showed glycosylation abnormalities due to mutations in G6PT1, G6PG3, and PGM1. All of these involve glucose-6-P metabolism (Figure 3). G6PT1 encodes the Glucose-6-P (51) translocater, which causes glycogen storage disease Ib; and G6PC3 encodes glucose-6-phosphatase catabolic-3. These disorders have profound effects on neutrophils: neutropenia, endoplasmic reticulum (ER) stress, and abnormal N- and O-linked glycans. Abnormal glycosylation in particular affects gp91(phox), the electron-transporting component of the NADPH oxidase, which is critical for the oxidative burst. This leads to a poor oxidative response and increased ER stress causes excessive apoptosis. Both N- and O-glycan chains were truncated with many lacking galactose and sialic acid. However it was unclear whether N-glycosylation sites were fully occupied. This is important, since tunicamycin causes similar ER stress by generating unoccupied sites.

How these two genes exert their effects on glycosylation is unknown, but deficiency of galactose and sialic acid on both N- and O-linked glycans suggest that it involves insufficient supply of UDP-Gal. Exome sequencing showed two patients with mutations in PGM1 (Glc-1-P→Glc-6-P) causes hypoglycemia and liver abnormalities and results in both absence of N-glycan chains and insufficient galactosylation/sialylation (52, 53). Incomplete glycan chains could be due to PGM1 effects on UDP-Gal pool through the well-known metabolic steps (Figure 3). There is no explanation for how PGM1 deficiency causes the absence of entire glycan chains from proteins. However, uncontrolled galactosemia that leads to Gal-1-P accumulation (54) and hereditary fructose intolerance and Fru-1-P accumulation, produce the similar glycosylation abnormalities (55). Intracellular accumulation of various sugar phosphates or other metabolic by products appears to prevent full N-glycosylation in selected cells and tissues. Only Man-6-P has been shown to have an effect on LLO levels (45). It is clear that mutations in fundamental glucose utilization pathways, which focus exclusively on their role in energy metabolism, must now also consider the cell-specific effects on glycosylation.

While Tf analysis led to identification of 35 glycosylation disorders spanning a large clinical spectrum, it focused most of the attention on lack of N-glycans. Accumulation of toxic, incomplete or unnatural products (as seen in uncontrolled galactosemia) is seldom considered. Disorders involving dolichol biosynthesis or activation of
mannose and its downstream donors could also impair synthesis of GPI anchors, O-mannose glycans, and C-mannosylation (56), but few studies probe other types of glycans (57). Synthesis of dolichol-P-Man requires a complex containing DPM1, 2 and 3, each encoded by a different gene. DPM1 is the catalytic subunit and DPM3 tethers the complex to the ER membrane, whereas DPM2 stabilizes DPM1 and enhances binding of Dol-P-Man (59). A single patient with mutations in DPM3 showed a mild and late onset muscular dystrophy, but did not have any of the typical symptoms seen in Dol-P-Man-deficient patients. The mutations disrupt the DPM1/DPM3 binding interface (57). Two families with much more severe pathology typical of CDG patients had mutations in DPM2 with muscular dystrophy with reduced O-Mannose staining in muscle (60).

**α-DYSTROGLYCANOPATHIES**

An entire set of congenital muscular dystrophies (CMD) with variable severity result from defects in the biosynthetic pathway that adds O-mannose linked glycans to α-dystroglycan (αDG). This peripheral membrane component of the dystrophin–glycoprotein complex (DGC) is located in muscle, nerve, heart, and brain. αDG is one of the two subunits of the DGC, bridging the ECM to the cytoskeleton. αDG and βDG are derived from a single gene, DAG1. In muscle, cytoskeletal actin is linked to βDG, which spans the cell membrane. The extracellular domain of βDG binds to αDG, which in turn binds to laminin in the extracellular matrix via its glycan-containing domain. The degree and types of αDG glycosylation vary in different tissues. Monoclonal antibodies against the glycans have been key to identifying glycosylation-related defects that affect αDG.

Collectively these disorders, called α-dystroglycanopathies, result from mutations in 7 genes and more will likely be found. Other proteins probably contain these glycans and might contribute to CMD pathology in the brain, since brain-specific deletion of αDG does not reduce the amount of those glycans. Recently, Dwyer et al. reported that these glycans occur on a receptor protein tyrosine phosphatase and the secreted form, phosphacan, and that a mutant mouse strain with mutations in POMGnT1, the second enzyme in the pathway gives a lower MW and loss of the glycan antigen (61).

Defining the structure of the critical glycan(s) and their location on the protein has been challenging (34, 62). The key laminin-binding glycans contain Man-6-P resides in an acid-resistant diester linkage. Details of biosynthesis are nebulous, but Man-6-P addition is unrelated to the lysosomal enzyme-targeting pathway. LARGE is a protein with 2 putative glycosyltransferase domains and functions as a co-polymerase that adds a variable number of alternating units of α1,3Xyl and β1,3GlcA to the protein (14). The acceptor sugar and structure of the glycan is unknown. Solving this long-standing enigma relied on compositional analysis of expressed αDG and testing a series of glycosides as acceptors for expressed LARGE.

Walker-Warburg Syndrome (WWS) is a clinically defined, severe CMD. While about 50% of the cases result from defects in POMT1/2 the remaining patients have defects in unknown genes. One study showed that a putative glycosyltransferase, GTDC2, is mutated in some WWS based on whole exome analysis and homozygosity mapping of consanguineous families (63). Morpholino knockdown of gtdc2 in zebrafish duplicated the WWS phenotype. Two additional studies using a combination of linkage analysis and exome sequencing identified a large number of patients with recessive mutations in ISPD. One study complemented patients’ fibroblasts with wild-type ISPD (62) and the other used zebrafish morphants to recapitulate the human phenotype including hydrocephalus, smaller eye size, muscle degeneration and reduced αDG glycosylation (34). The gene ISPD, (isoprenoid synthase domain-containing) is the human homolog of a series of genes found in plants and prokaryotes in the non-mevalonate (MEP) pathway of isoprenoid synthesis (64). However, this pathway does not exist in chordates, so its biochemical function, presumably in the biosynthesis of the O-mannosyl glycan is unknown. Two homologs in bacteria have cytidylyltransferase activity and are used in the synthesis of CDP-methyl-erythritol and CDP-ribitol. One suggestion (34) is that the gene is involved in CTP-driven substrate activation to a
precursor in the pathway, but this idea awaits more structural information on the glycan.

Human glycosylation defects in the isoprenoid-derived dolichol pathway are well established. Mutations in SRD5A3, the long-sought polyprenol reductase, show the existence of another, unknown route of dolichol biosynthesis (65, 66). Mutations in DDHDS, a cis-isoprenyltransferase cause retinitis pigmentosa, but no other clinical deficits (67, 68). Knockdown of NUS1, the NogoB receptor that contains a cis-isoprenyltransferase domain reduces the level of LLO and decreases N-glycosylation (69). To date, no defects are known in this likely CDG target gene.

DEFECTS IN GPI ANCHOR SYNTHESIS

Whole sequencing and autozygosity mapping identified 6 disorders in GPI anchor biosynthesis: PIGA, PIGL, PIGM, PIGN, PIGO and PIGV. PIGA encodes the first step in GPI anchor synthesis, and somatic mutations in the X-linked gene cause the well-known haematological disorder PNH that results in erythrocyte lysis (70). A lethal germline mutation in PIGA was found in one patient who appeared to retain residual activity (71).

PIGL carries out the second step of the pathway, de-N-acetylation of N-acetylgulosaminylphosphatidylinositol (GlcNAc-PI) and mutations in it cause CHIME syndrome with ocular coloboma, heart defects, ichthyosis, mental retardation and ear anomalies. PIGM is a mannosyltransferase that adds the first mannose to the core GPI (72). Its decrease caused venous thrombosis and seizures (73). However, the mutation occurs at an Sp1 transcription-binding site. Butyrate restores normal PIGM transcription and cell surface GPI expression in the patient’s lymphoblasts. Two-week treatment with phenylbutyrate eliminated seizures and improved motor skills (74). PIGN encodes the ethanolamine phosphate transferase, which adds the ethanolamine phosphate to the first mannose on the GPI anchor. Mutations in PIGN cause multiple congenital anomalies, including hypotonia and seizures (23).

Mutations in the second mannosyltransferase, PIGV, were first identified as the cause of hyperphosphatasia and mental retardation syndrome (75). Patients with a similar phenotype who lacked mutations in PIGV had mutations in PIGO, an ethanolamine phosphate transferase (76). Both had reduced level of GPI-anchored substrates at the cell surface. Alkaline phosphatase (ALP) is normally GPI-anchored, but it is secreted into the blood, accounting for the characteristic of these two disorders. The other GPI disorders do not result in ALP secretion. It appears secretion of ALP depends on GPI transamidase removal of the C-terminal GPI attachment signal peptide and GPI addition. Defects where shorter, non-mannosylated GPI chains accumulate, result in ALP degradation, while it is secreted from cells with mannose-containing, incomplete chains. Transamidase appears to recognize the presence of incomplete, mannose containing chains and cleaves a hydrophobic signal peptide resulting in secretion (77).

FRINGES OF GLYCOSYLATION DISORDERS

Most glycosylation disorders are caused by defects in genes that conform to our current concepts. Others suggest an expanded view might be better. One case in point is a glycosylation disorder caused by mutations in the gene TMEM165 (aka TPARL) (78). Transferrin and total serum N- and O-glycans from patients are deficient in sialic acid and galactose, suggesting a defect in the Golgi. Staining with Golgi markers TGN46 and GM130 showed a dilated morphology and fragmented trans-Golgi network. TMEM165 encodes a 324 amino acid membrane protein with 6-predicted transmembrane regions. It is ubiquitously expressed and about 230 residues are highly conserved in eukaryotes and many bacteria. Several motifs emerge, but none indicates function. Patient fibroblasts are deficient in the late Golgi localized protein. It leads to modest decreased sialylation in patient and siRNA knockdown in HEK cells. But the function eluded detection and the best guess was a cation (proton, Ca ?) pump. Conservation from bacteria to human suggests a very ancient function, and previous glycosylation disorders in Golgi are known to affect pH homoeostasis.

Poor N-glycosylation causes ER stress (79) and cellular responses are aimed at reducing the stress. Glycosylation inhibitors such as tunicamycin or genetic defects upregulate ER stress response (80) which includes dampening
protein synthesis or up regulating various molecular chaperones to restore homeostasis. Hopelessly misfolded ER-located glycoproteins are dispatched to the cytoplasm for proteasomal degradation, but first the N-glycan chains must be stripped. The gene \textit{NGLY1} encodes a stripper enzyme that clears the glycan, and exome mapping identified a patient with mutations that eliminated the protein (81). This may be considered the first “Congenital Disorder of Deglycosylation” and is predicted to cause accumulation of N-glycosylated proteins in the cytoplasm and possibly ER stress. Accumulation of the undegraded material in the cytoplasm could have separate toxic effects.

CONCLUSIONS AND PERSPECTIVES
A thorough whole exome sequencing study (3) focused on 100 patients with intellectual disability (ID) and solved about half of them by employing sophisticated informatics to identify the gene and confirmation by Sanger sequencing. Causality was based on programs used to predict mutations’ effects on the protein structure or by analogy to known genes in the same or related pathway. Surprisingly, the study identified 22 patients with potentially causative \textit{de novo} mutations in novel candidate genes. Sixteen patients had mutations in known ID genes. Whole exome/genome sequencing will continue to identify new glycosylation disorders. Biochemical markers will help focus the search, but these approaches will also identify glycosylation-related genes that the serum biomarkers missed or in patients who were never tested for the markers. Both approaches will continue to focus on new genes that impact glycosylation, and biochemical analysis will continue its prominent role to provide a physiological context and basis for therapies.

REFERENCES


60. Barone R., Aiello C., Race V., Morava E., Foulquier F., Riemersma M., Passarelli C., Concolino D., Carella M., Santorelli F., Vleugels W., Mercuri E., Garozzo D., Sturiale L., Messina S., Jaeken J.


Understanding Human Glycosylation Disorders: Biochemistry Leads the Charge


ACKNOWLEDGEMENTS

The author wishes to thank Bobby Ng for help in preparing the figures and Amy Zimmon for administrative assistance. This work was supported from The Rocket Fund, The Bertrand Might Research Fund and R01DK55615.

FIGURE LEGENDS

FIGURE 1. Schematic of the N-glycosylation pathway. The upper circle represents the Endoplasmic Reticulum. The early steps involve GlcNAc, Glc, and Man addition to a lipid-linked oligosaccharide (LLO) assembly on dolichol-P using UDP-GlcNAc and GDP-Man donors on the cytoplasmic face. The partially completed glycan flips to the luminal side where it is completed using donors Dol-P-Man and Dol-P-Glc to form Glc3Man9GlcNAc2-P-P-Dol, which is then transferred to proteins in the ER. The lower circle denotes processing of the N-glycans using a series of glycosidases and glycosyl transferases that require UDP-GlcNAc, UDP-Gal and CMP-Sia transported into the Golgi. Sialic acid, Galactose.
FIGURE 2. GPI-anchor synthesis. This schematic shows the step-wise pathway for GPI anchor assembly including the reaction, name of the enzymes and genes involved. Red highlights show known glycosylation disorders. glucosamine, ethanolamine phosphate. (Adapted from, “Essentials of Glycobiology, Second Edition” Cold Spring Harbor Laboratory Press)

FIGURE 1
FIGURE 2

Mammalian cells

PIG-Q  PIG-H
PIG-C  PIG-P
PIG-A  DPM-2
PIG-Y

PIG-W  Gln-N-PI

PIG-M  Gln-N-aPI
PIG-X
ManGln-N-aPI

PIG-V  ManManGln-N-aPI

PIG-N  Man(EnP)ManGln-N-aPI

PIG-B  ManMan(EnP)ManGln-N-aPI

PIG-O  EnPManMan(EnP)ManGln-N-aPI

PIG-F

PG-17  EnPMan(EnP)Man(EnP)ManGln-N-aPI

PIG-S  PIG-K
PIG-U  PIG-T
GAA-1

Protein

PGAP-1

Protein

ER lumen
Cytoplasm
ER membrane

1. Gln-Nac-PI
2. Gln-N-PI
FIGURE 3

Biosynthesis and interconversion of monosaccharides
### TABLE 1. GLYCOSYLATION DISORDERS IDENTIFIED IN 2011-2012

<table>
<thead>
<tr>
<th>Pathways</th>
<th>Disorder</th>
<th>Gene</th>
<th>Function</th>
<th>OMIM</th>
<th>Identification Method</th>
<th>Clinical Phenotype</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>N-Linked</td>
<td>DDOST - CDG</td>
<td>DDOST</td>
<td>Subunit of the OST complex</td>
<td>614507</td>
<td>Exome &amp; Targeted Sequencing</td>
<td>Failure to thrive, reflux, developmental delay, infections, osteopenia, hypotonia, strabismus, liver dysfunction</td>
<td>(31)</td>
</tr>
<tr>
<td></td>
<td>DPM2 - CDG</td>
<td>DPM2</td>
<td>Dol-P-Man Synthase Complex</td>
<td></td>
<td>Biochemical</td>
<td>Developmental delay, seizures, microcephaly, hypotonia, increased serum creatine kinase, early death</td>
<td>(60)</td>
</tr>
<tr>
<td></td>
<td>ALG13 - CDG</td>
<td>ALG13</td>
<td>UDP-GlcNAc transferase</td>
<td></td>
<td>Exome</td>
<td>Epilepsy, liver dysfunction, infections, bleeding, microcephaly, nystagmus, optic nerve atrophy, early death</td>
<td>(52)</td>
</tr>
<tr>
<td></td>
<td>DHDDS - CDG</td>
<td>DHDDS</td>
<td>Dehydrodolichol diphosphate synthase</td>
<td>613861</td>
<td>Exome</td>
<td>Retinitis pigmentosa only</td>
<td>(62, 63)</td>
</tr>
<tr>
<td></td>
<td>MAN1B1 - CDG</td>
<td>MAN1B1</td>
<td>α-1,2-mannosidase</td>
<td>614202</td>
<td>Mapping &amp; Targeted Sequencing</td>
<td>Non-Syndromic Intellectual Disability</td>
<td>(82)</td>
</tr>
<tr>
<td>Multiple</td>
<td>TMEM165 - CDG</td>
<td>TMEM165</td>
<td>Unknown</td>
<td>614727</td>
<td>Mapping</td>
<td>Psychomotor and growth delay, short stature, dysmorphism, hypotonia, eye abnormalities, microcephaly, liver dysfunction, and skeletal dysplasia</td>
<td>(78)</td>
</tr>
<tr>
<td></td>
<td>PGM1 - CDG</td>
<td>PGM1</td>
<td>Interconversion of Glc-1-P and Glc-6-P</td>
<td>612934</td>
<td>Exome</td>
<td>Liver dysfunction, cleft palate, coagulopathy, delayed growth</td>
<td>(52, 53)</td>
</tr>
<tr>
<td></td>
<td>GSD – G6PC3</td>
<td>G6PC3</td>
<td>Glucose-6 phosphatase, catalytic, 3</td>
<td>612541</td>
<td>Biochemical</td>
<td>Severe congenital neutropenia</td>
<td>(51)</td>
</tr>
<tr>
<td></td>
<td>GSD – G6PT1</td>
<td>G6PT1</td>
<td>Glucose-6-phosphate transporter</td>
<td>232220</td>
<td>Biochemical</td>
<td>Glycogen storage disease type 1B</td>
<td>(51)</td>
</tr>
<tr>
<td></td>
<td>ST3GAL3 - CDG</td>
<td>ST3GAL3</td>
<td>Sialyltransferase for sLe-a</td>
<td>611090</td>
<td>Mapping &amp; Exome</td>
<td>Non-Syndromic Intellectual Disability</td>
<td>(83)</td>
</tr>
<tr>
<td>GPI Anchor</td>
<td>GPI – PIGA</td>
<td>PIGA</td>
<td>GlcNAc-PI synthesis</td>
<td>300868</td>
<td>Exome</td>
<td>Cleft palate, seizures, contractures, brain structural malformations, early death</td>
<td>(71)</td>
</tr>
<tr>
<td></td>
<td>GPI – PIGL</td>
<td>PIGL</td>
<td>GlcNAc-PI de-N-acetylase</td>
<td>280000</td>
<td>Exome</td>
<td>Coloboma, congenital heart disease, ichthyosiform dermatosis, intellectual disability and hearing loss</td>
<td>(20)</td>
</tr>
<tr>
<td></td>
<td>GPI – PIGN</td>
<td>PIGN</td>
<td>GPI ethanolamine phosphate transferase</td>
<td>614080</td>
<td>Mapping</td>
<td>Hypotonia, psychomotor delay, seizures, dysmorphic features, anomalies in cardiac, urinary, and gastrointestinal systems</td>
<td>(23)</td>
</tr>
<tr>
<td></td>
<td>GPI – PIGO</td>
<td>PIGO</td>
<td>GPI ethanolamine phosphate transferase</td>
<td>614749</td>
<td>Exome</td>
<td>Hyperphosphatasia with mental retardation syndrome</td>
<td>(76)</td>
</tr>
<tr>
<td>O-Mannose</td>
<td>Walker-Warburg syndrome</td>
<td>GTDC2</td>
<td>Putative glycosyltransferase</td>
<td>614830</td>
<td>Mapping &amp; Exome</td>
<td>Brain and eye malformations, muscular dystrophy</td>
<td>(64)</td>
</tr>
<tr>
<td></td>
<td>Walker-Warburg syndrome</td>
<td>ISPD</td>
<td>Isoprenoid synthase domain containing putative glycosyltransferase</td>
<td>614643</td>
<td>Mapping &amp; Exome</td>
<td>Brain and eye malformations, muscular dystrophy</td>
<td>(34, 65)</td>
</tr>
<tr>
<td>Other</td>
<td>NGLY1 - CDG</td>
<td>NGLY1</td>
<td>N-Glycanase-1</td>
<td>610661</td>
<td>Exome</td>
<td>Developmental delay, epilepsy, liver dysfunction, movement disorder and absent tears</td>
<td>(81)</td>
</tr>
</tbody>
</table>